5Pederson J R,Olsson A G,Faergeman V,et al.Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simavastatin Survival Study (4s)[J].Circulation,1998,97(15):1453-1460.
6Maker G C,Wanrica J M,Sacks F W,et al.For the Cholesteorl and Recurrent Events (CARE)investigators.Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations[J].J Am Coil Cardiol,1999,34(1):106-112.
4[1]Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowing with simvastatin in 20536high-risk individuals: a randomized placebo-controlled trial.Lancet, 2002, 360:7-22.
5[2]Cox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 2004,109: Ⅱ 42- Ⅱ 48.
6[3]Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003, 24: 225-248.
7[4]Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother, 2004, 38:110-118.
8[5]Horne BD, Muhlestein JB, Carlquist JF, et al. Intermountain Heart Collaborative (IHC) Study Group. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation, 2003,107: 258-263.
9[6]Gupta S. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment? Int J Cardiol, 2004, 96:131-139.
10[7]Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005,352: 20-28.
